Immunotherapy duo shows promise against rare lung cancer in chinese trial

NCT ID NCT05136677

Completed Disease control Sponsor: Bristol-Myers Squibb Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether a combination of two immunotherapy drugs (nivolumab and ipilimumab) works better than standard chemotherapy for Chinese patients with advanced pleural mesothelioma, a rare cancer of the lung lining. 102 patients who could not have surgery were randomly assigned to receive either the immunotherapy combo or chemotherapy. The main goal was to see if the immunotherapy helped patients live longer. The study is now complete.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

malignant mesothelioma malignant pleural mesothelioma Mesothelioma, Malignant

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MESOTHELIOMA, MALIGNANT

Contacts and locations

Locations

Local Institution - 0001

Shanghai, Shanghai Municipality, 200030, China
Local Institution - 0003

Changchun, Jilin, 130021, China
Local Institution - 0004

Shenyang, Liaoning, 110042, China
Local Institution - 0005

Changsha, Hunan, 410013, China
Local Institution - 0006

Zhengzhou, Henan, 450003, China
Local Institution - 0007

Tianjin, Tianjin Municipality, 300052, China
Local Institution - 0009

Beijing, Beijing Municipality, 100142, China
Local Institution - 0010

Kunming, Yunnan, 650106, China
Local Institution - 0012

Ningbo, Zhejiang, 315010, China
Local Institution - 0013

Harbin, Heilongjiang, 150081, China
Local Institution - 0014

Hangzhou, Zhejiang, 310003, China
Local Institution - 0015

Yangzhou, Jiangsu, 225001, China
Local Institution - 0016

Ningbo, Zhejiang, 315041, China
Local Institution - 0018

Tianjin, Tianjin Municipality, 300060, China
Local Institution - 0020

Hangzhou, Zhejiang, 310005, China
Local Institution - 0021

Shenyang, Liaoning, 110044, China
Local Institution - 0023

Wuhan, Hunan, 430023, China
Local Institution - 0029

Chengdu, Sichuan, 610041, China
Local Institution - 0030

Qingdao, Shandong, 266003, China
Local Institution - 0033

Taiyuan, Shanxi, 030000, China
Local Institution - 0037

Jinan, Shandong, 250117, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.